Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).
| NCPE Assessment Process | Ongoing |
| Rapid Review commissioned | 03/12/2019 |
| Rapid Review completed | 27/01/2020 |
| Rapid Review Outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care. |